ADMA BIOLOGICS, INC. Total Long-Term Debt
ADMA BIOLOGICS, INC. (ADMA) had Total Long-Term Debt of $196.59 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-08-05
- 2026-06-30: Long-term Debt $196.59M.
- 2026-03-31: Long-term Debt $196.87M.
- 2025-12-31: Long-term Debt $72.14M.
- 2025-09-30: Long-term Debt $72.43M.
| Period end | Long-term Debt |
|---|---|
| 2026-06-30 | $196.59M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $196.87M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $72.14M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $72.43M 10-Q · filed 2025-11-05 |
| 2024-12-31 | $72.34M 10-K · filed 2026-02-25 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-13 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 |
| 2018-12-31 | $2.76M 10-K · filed 2020-03-13 |
| 2018-09-30 | $2.76M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $2.76M 10-Q · filed 2018-08-10 |
| 2018-03-31 | $2.76M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $2.76M 10-K · filed 2019-03-13 |
| 2017-09-30 | $1.79M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $1.79M 10-Q · filed 2017-08-11 |
| 2016-12-31 | $1.79M 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |